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Strategies for 
tumor necro 
Georges E. Grau and Daniela N. Mbnel 
new technique to deliver in 
z/iz10, very efficiently, an in- 
hibitor of tumor necrosis 
which, in the case of gene knockout, 
would require double- or triple- 
knockout mice to be generated. 
factor a (TNF-a) has been dcscribcd 
by J. Kolls, K. Peppcl, M. Silva and 
B. Beutler’. TNF-a is a central me- 
diator in sepsis and several other 
immunopathological conditions. 
Under experimental conditions, 
in viva inhibition of TNF-a is 
efficient at preventing a wide array 
of tissue lesions, and so blocking 
the activity of this cytokine has 
therapeutic potcntiaP”. Ongoing 
clinical trials also indicate that 
anti-TNF-a monoclonal antibody 
treatment has promising appli- 
cations, for example, in the treat- 
ment of Crohn’s disease (S. van 
Deventer and colleagues’) and of 
rheumatoid arthritis (M. Feldman 
and colleague?). However, there 
are drawbacks to passive immuniz- 
ation (see Ref. 1 for a discussion), 
as there are with other methods 
of blocking TNF-a activity, for 
example, by deletion of the genes 
encoding TNF-a or the TNF-a re- 
ceptor in experimental animals (rcp- 
resented schematically in Fig. 1). 
Thus, the method developed by 
Kolls et al. for the in viva delivery 
of a chimeric TNF-a inhibitor using 
an adcnovirus vector is promising, 
especially for use in other fields of 
experimental biology. 
The inhibitor was expressed in 
high titers over a long time and the 
level and duration of expression 
were correlated: the higher the titer 
of inhibitor adenovirus that is given, 
the longer expression persists. As 
a result of this sustained inhibition 
of TNF-a, thcsc transduced animals 
have an impaired resistance to bac- 
terial infection. Thus, in uivo trans- 
duction by this method obviously 
allows extremely high levels of 
expression of any gene of interest. 
One of the most impressive and 
important aspects of this method 
is the uncommonly high lcvcl of 
production of the TNF-a inhibitor 
(as much as 1 mgmll’ is found in 
circulating blood). However, the 
expression stops abruptly and the 
mechanisms by which this occurs 
remain incompletely understood. 
The lifespan of the transduced cells 
may be limited, but experiments to 
tackle this question have not been 
carried out. Advantages and disad- 
vantages of this technique of in uiuo 
delivery of inhibitors over others are 
summarized in Table 1. The major 
advantage of in uivo expression 
of inhibitors over the application 
of monoclonal antibodies is the 
guaranteed administration of the 
proteins for a longer period of time. 
Compared with the technology of 
generating transgenic animals, the 
in vim transduction or transfection 
methods involve impressively simple 
manipulations, and there is no trig- 
gering of compensatory mechan- 
isms and/or developmental changes. 
These latter two ‘side effects’ seem 
to have been largely overlooked in 
recent papers. Another major ad- 
vantage is the possibility to transfect 
with a combination of inhibitors, 
Other approaches to expression 
of inhibitor molecules in viva have 
already demonstrated the value of 
this technique for possible gene 
therapy. Stable transfection of syn- 
ovial cells ex viva with the gene en- 
coding the interleukin-l-receptor 
antagonist protected rabbits from 
arthritis9,10. In this case, the inhibi- 
tor was expressed only transiently 
in the synovium. A further positive 
aspect, especially of organ-specific 
expression, is that optimal pro- 
tection against pathology can be 
achieved in this way. Localized de- 
livery of a given inhibitor by gene 
transfer may be more biologically 
effective than delivery of this in- 
hibitor by injection9,‘0. Successful 
in viuo transfection with liposomc- 
DNA complexes has also been rc- 
ported in a model involving inha- 
lation of liposomes containing the 
gene encoding the cystic fibrosis 
transmembrane conductance regu- 
lator for the treatment of cystic 
fibrosisi’. 
The adenoviral construct used 
for the in uiuo transduction led to 
the expression of the inhibitor in 
endothelial cells and hepatocytes. 
In fact, while adenoviruses can in- 
feet many types of cells in vitro, in 
viuo, they infect almost exclusively 
hepatocytes and endothelial cells. 
This is because the endothelium is 
susceptible to infection, but forms 
an effective barrier against the 
virus, preventing it from infecting 
most other cells cxccpt hepatocytcs, 
which can be infected because of 
the fcncstration of the endothelium 
there (B. Beutler, pers. commun.). 
Using viral vectors for in viuo 
transduction always carries the po- 
tential risk of infection. Kolls et al. 
claim that the TNF-a-receptor- 
immunoglobulin construct does 
not become integrated into the cell 
genome, but rather remains epi- 
somal. The adenoviral genome used 
was adapted to be replication dc- 
fective, and this may be sufficient 
to ensure, as the authors claim, that 
the transferred gene remains epi- 
somal. While this seems to be safe 
enough for generating conditional 
knockouts that are used for basic 
research, for the purpose of gene 
therapy, it is absolutely required 
to prove formally that the trans- 
gene stays episomal and dots not 
become integrated. This could be 
addressed by Southern blotting, 
but cvcn this approach may not 
inhibition 
factor in viv 
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Fig. 1. Tumor necrosis factor a (TNF-a) functions can be inhibited in various ways: by addition of 
polyclonal or monoclonal neutralizing antibodies, soluble TNF-a receptors (TNF-aR; schematically 
represented by their four cysteine-rich domains) or soluble receptor-immunoglobulin constructs 
(sTNF-R-lg). Alternatively, the genes encoding either TNF-a or TNF-oR can be knocked out (KO). 
These methods have been used by several groups to decipher mechanisms of TNF-a action and 
to suggest potential therapeutic approaches (see text). mAb, monoclonal antibody. 
be sensitive enough to provide a 
definitive answer. 
The reduced resistance to bac- 
terial infection that is the physio- 
logical consequence of inhibition 
of TNF-a is not surprising, but 
rather proves the efficacy of the 
method. However, possible side 
effects of the adenoviral trans- 
duction need to be kept in mind in 
interpreting the data. Despite the 
absence of viral replication, there 
seem to be signs of viral infection, 
such as liver inflammation, in the 
transduced animals. Furthermore, 
the production of interferon is 
likely to be upregulated and might 
modulate the effects of TNF-a re- 
sponses (B. Beutler, pers. com- 
mun.). With the method used by 
Kolls et al., TNF-a can be blocked 
efficiently without leading to the 
abnormalities of development (that 
is, failure to thrive and lymphoid- 
tissue aplasia) that occur in mice 
injected at birth with anti-TNF-a 
antibody . l2 The adenoviral vcctoi 
has also been injected into newborn 
mice via the external jugular vein 
(B. Beutler, pers. commun.): the 
growth rate of these mice was simi- 
lar to that of littermates that received 
a control virus construct contain- 
ing the gene for P-galactosidasc; 
in particular, their thymuses and 
lymph nodes were of normal weight. 
Interestingly, however, a complete 
lymph-node aplasia has also been 
reported recently in TNF-a, TNF-P 
knockout micei3. Taken together, 
the data from all three experimen- 
tal systems suggest that some of the 
effects seen using polyclonal anti- 
TNF antibodies are due to inhi- 
bition of TNF-P (or lymphotoxin, 
IT). The polyclonal antibody used 
in Ref. 12 also neutralizes the ac- 
tivity of TNF-P (N.H. Ruddle, pers. 
commun.). In fact, the whole dis- 
cussion on blocking TNF-a may 
be useful for blocking functions of 
TNF-fi, the role of which may well 
soon be understood better and rec- 
ognized as being of equal import- 
ance as that of TNF-a. Indeed, 
while TNF-a does not bind to the 
Table 1. Advantages and disadvantages of some methods for inhibition of tumor necrosis factor 
dvantages 
Disadvantages 
Alteration of gene expression by: 
Mutation (gene knockout) Viral transduction Liposome-DNA transfection 
Stable 
Any health status 
Complete 
Very high expression 
Any genetic background 
Any age 
Any health status 
Any gene (even if 
required for embryonic 
development) 
Technically simple 
Any genetic background 
Any age 
Any health status 
Any gene (even if 
required for embryonic 
development) 
Compensatory mechanisms Symptoms of viral 
likely to be triggered infection 
Demanding technology Triggering of immune 
response 
Demanding technology 
Nonpermanent 
expression 
Incomplete (locally 
restricted) 
Potential risk of 
insertion into the 
genome 
Lower efficiency 
(Neuro)toxicity 
Nonpermanent 
expression 
Incomplete (locally 
restricted) 
Potential risk of 
insertion into the 
genome 
Inhibitor administration 
Any genetic background 
Any age 
Any protein 
Difficult to access 
certain sites 
Requires large amounts 
of purified proteins 
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LT receptor, TNF-P (or LT) can 
bind to both pSS and ~75 TNF-a 
receptors. 
It will be attractive to evaluate 
the response of these TNF-inhibitor- 
expressing mice in the context of 
several pathological conditions. The 
technique described by Kolls et al. 
will certainly become a very use- 
ful tool to analyse cell-cell intcr- 
actions on a molecular level in in 
vim models. The significance of the 
method of Kolls et al. may not be as 
a suggested method for gene ther- 
apy, but rather as an elegant tech- 
nique to replace the USC of knock- 
out mice, in that it might create a 
‘conditional knockout’ for any gene 
of interest. 
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Plant-virus movement: de novo 
process or redeDloved machinerv? 
d I d 
Andy 1. Made 
T hree papers have appeared recently that provide a basis for the view that cell-to- 
cell trafficking of macromolecules 
through plant plasmodesmata is not 
unique to virus infection, but that 
plant viruses exploit an existing 
mechanism of cellular communi- 
cation in plants to spread the infec.- 
tion through the tissues’-“. This view 
has been expanded recently to in- 
clude the idea that plasmodesmata 
mediate a ‘supracellular’ control of 
plant processes”. 
It has long been recognized that 
plant viruses encode proteins that 
mediate viral movement through 
plasmodesmata, and that these pro- 
teins can modify plasmodesmal 
structure and function4J. Pioneering 
work in this field used the tobacco 
mosaic virus (TMV) movement pro- 
tein (Ml’) P30 and the technique 
of microinjection to assess the size 
exclusion limit (SEL) of plasmo- 
desmata in the presence and ab- 
sence of the MP. By microinjecting 
fluorescently labelled dextrans of 
different sizes into cells in trans- 
genie tobacco plants expressing P30 
and monitoring their diffusion into 
adjacent cells, the normal SEL of 
<I kDa in non-transformed tissue 
was shown to increase to >I0 kDa 
in the presence of P30 (Ref. 6). This 
increase corresponds to a change 
in the functional diameter of the 
microchannels within plasmo- 
desmata from 1.2-1.8 nm to 2.4- 
3.1 nm, which is still too small to 
allow the passage of the intact virus 
or of its genomic RNA. Howcvcr, 
I’30 can bind to and denature 
single-stranded (ss) RNA to pro- 
duce long, thin (~2 nm) ribonucleo- 
protein complexes7, which might 
be able to pass through the altered 
microchannels. 
Some other viruses have been 
shown to have similar properties: 
their MP can bind to nucleic acids 
and their coat protein is not 
necessary for cell-to-cell move- 
ment. However, this is not always 
the case: cell biological obser- 
vations of virus particles within 
structurally modified plasmo- 
desmata suggest that a further class 
of viruses, including the como- 
viruses8 and the caulimoviruses9, 
move as intact virions. 
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MPs traffic through 
plasmodesmata 
TMV and two functionally related 
viruses, red clover necrotic mosaic 
virus (RCNMV) and bean dwarf 
mosaic virus (BDMV), are the sub- 
jects of the three recent papers men- 
tioned above’-“. Whereas TMV and 
RCNMV have ssRNA genomes and 
single Ml’s (TMV P30; RCNMV 
35 kDa protein), BDMV (a gemini- 
virus) has a genome of ssDNA and 
two proteins (BLl and BRl) that 
arc necessary for a spreading infec- 
tion in plants. These papers all re- 
port a novel and elegant approach 
to assess the effect of MI’s on plas- 
modesmal function. The proteins 
were expressed in Escherichia coli, 
and the purified recombinant pro- 
tcins were directly comicroinjected 
with fluorescent dextrans into meso- 
phyll cells of host plants and the 
SEL assessed. This approach was 
extended in two cases1x3 by study- 
ing the fate of fluorescently labelled 
MI’ and by directly measuring 
the ability of the Ml’ to transport 
nucleic acids by co-injecting MP 
and fluorescently labcllcd RNA or 
DNA. 1’30, RCNMV 35 kDa pro- 
tein and BDMV RI,1 protein all in-, 
crease the SEI, of plasmodcsmata 
